Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

tfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalininclude risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective as consolidation therapy following treatment with a regimen of fludarabine and mitoxantrone for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 STAAR ... developer, manufacturer and marketer of minimally invasive ophthalmic products, ... investor conferences to review the Company,s recent financial results ... STAAR Surgical will present at the 38 th ... Boston at the Westin Waterfront Hotel ...
(Date:5/21/2013)... , May 21, 2013   RxAlly , ... nationwide, announces today the publication of a white ... Health Care System. The white paper highlights an ... and seeks public engagement to avert strains on ... Care refers to a range of individually-tailored, pharmacist-provided ...
(Date:5/20/2013)... , May 20, 2013  Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will highlight its efforts to expand research ... Flow Reserve (FFR) and iFR ® (Instant Wave-Free ... presentations and events at EuroPCR 2013 in ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4
... Study at the Annual Scientific Meeting of ... the American College of Rheumatology, ... cost-utility study supporting the adoption of EUFLEXXA(TM) (1%,sodium hyaluronate) intra-articular ... osteoarthritis (OA) of the knee at the American,College of Rheumatology,s ...
... Sustained and Dose-Dependent in Sub-Analysis of Phase II ... ... SCH 530348 (TRA), the,novel investigational antiplatelet agent in development by ... inhibitor of platelet,aggregation in a sub-analysis of the Thrombin Receptor Antagonist ...
Cached Medicine Technology:Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 2Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 3Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7
(Date:5/21/2013)... Delmar, NY (PRWEB) May 21, 2013 ... announce the release of his first two barbering DVDs. ... viewers are enrolled barber school , cosmetology school ... the opportunity to learn from an experienced teacher and ... in classic barbering from the 1920’s – 1960’s time ...
(Date:5/21/2013)... 21, 2013 Dimensional Insight, a developer ... that Western Maryland Health System, a 275-bed ... Diver Solution™ (Diver) to help it analyze its data ... customer to purchase Diver through Dimensional Insight’s recently announced ... most hospitals, Western Maryland has massive amounts of data ...
(Date:5/21/2013)... AAG Health, the leading age management and ... it has acquired the OligoScan test made by leading ... spectrophotometry technology, the OligoScan device is capable of measuring ... heavy metals, 20 trace elements (minerals), and oxidative stress ... such as mercury, lead, aluminum, and arsenic, will make ...
(Date:5/21/2013)... surgical management of non-small cell lung cancer (NSCLC) in ... the patient, according to a new study., "In most ... II NSCLC is surgery," said researcher Jayanth Adusumalli, MBBS, ... "In our study of more than 1,200,000 patients diagnosed ... and 2010, we found statistically significant racial disparities in ...
(Date:5/21/2013)... After the success of its inaugural 1,000 lb. ... Body Boot Camp Goderich will be hosting its 2nd Annual ... Goderich fitness center located at 199 Anglesea Street Goderich, ... goal is to inspire and motivate local community residents to ... The fee to participate is discounted to $40 for the ...
Breaking Medicine News(10 mins):Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 2Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 3Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 4Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 5Health News:First Series of Barbering DVDs Launched by Third Generation Master Barber Greg Zorian; DVDs Teach the Art of Men's Haircutting, Clipper Cutting, Fades and More 6Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 2Health News:AAG Health is the First Age Management Center in Florida to Offer the OligoScan 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... , ,Heart failure affects 5.8 million people in the U.S. ... year, most resulting from a build-up of body fluid in ... to pump effectively. The disease needs to be closely tracked ... be especially useful, UCLA researchers say. In ...
... Rockville, Md. -- With strong consumer interest in ... into a broader array of food productsnew standards ... ingredients are being proposed for public review and ... in the Food Chemicals Codex (FCC), offer comprehensive ...
... will gather in Minneapolis for a one-day summit on ... ST implantable cardioverter-defibrillator (ICD) leads, which recently underwent a ... Institute Foundation and Mayo Clinic have organized the summit ... who have these leads. Approximately 80,000 active patients ...
... heals all wounds Wound healing requires complex interactions ... cells. As healing progresses, the growth of new blood vessels ... (EPCs) are cells that come from the bone marrow and ... signals that direct their emigration from the bone marrow are ...
... that it is possible to selectively target and block ... The findings might offer a new therapy for this ... The animal study, by researchers at The Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
... Gordon HealthDay Reporter , MONDAY, Jan. 2 ... more effective at relieving neck pain in the long ... People undergoing spinal manipulation therapy for neck pain also ... home exercises. "We found that there are ...
Cached Medicine News:Health News:Critical quality considerations for probiotics offered in new draft FCC standards 2Health News:Critical quality considerations for probiotics offered in new draft FCC standards 3Health News:Summit seeks to inform electrophysiologists on Riata ICD recall 2Health News:Preview of articles to be published Jan. 3, 2012 2Health News:Preview of articles to be published Jan. 3, 2012 3Health News:Preview of articles to be published Jan. 3, 2012 4Health News:Preview of articles to be published Jan. 3, 2012 5Health News:Preview of articles to be published Jan. 3, 2012 6Health News:Preview of articles to be published Jan. 3, 2012 7Health News:Preview of articles to be published Jan. 3, 2012 8Health News:Anti-sense might make sense for treating liver cancer 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 2Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 3Health News:Spinal Manipulation, Home Exercise May Ease Neck Pain 4
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... assayed quality control material used for monitoring the ... It is for specific use on Bayer analyzers ... 288, and 270) and the AVOX Systems CO-Oximeters ... used on the IRMA TRUpoint®. CC 527 is ...
... 623 is an assayed quality control material for ... in four (4) levels for monitoring analyzer performance ... may be used on multiple test analyzers (such ... Radiometer 600). QC623 is also for use on ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: